Albax

Quick links to important sections

Albax

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Albax

Property Description
Active ingredient Albendazole (INN)
Form Tablet, Oral Suspension
Pharmacological class Anthelmintic Agent
General purpose Clearing parasitic worm infections
Origin Synthetic Benzimidazole Carbamate

Albax: Identity, Origin, and Pharmacological Class

Albax is a prescription medicine containing Albendazole as its sole active ingredient, which belongs to the benzimidazole carbamate chemical family. Chemically, it is classified as a synthetic compound, a small molecule drug that acts as a broad-spectrum anthelmintic agent. This designation confirms its primary purpose is the selective intervention against parasitic worms, known as helminths. This medication is clinically recognized by major health organizations for its effectiveness against a wide variety of these organisms. This means the drug is globally recognized as an essential tool for combating numerous parasitic infections.


Composition and Available Forms of Albendazole

The physical preparation of the medicine is designed for efficacy via the orally administered route. Albendazole is typically supplied as a film-coated tablet and a liquid oral suspension. The availability of these distinct pharmaceutical preparations is a key feature, as the suspension form allows for reliable administration to diverse patient groups, notably children, who may struggle with swallowing solid tablets. The foundational composition consists of the active Albendazole substance plus a pharmaceutically inert excipient base, suitable for ingestion.


The General Therapeutic Purpose of Albax

The fundamental role of Albax is defined by its ability to resolve parasitic worm infections by targeting their survival mechanisms. The active ingredient achieves this by selectively disrupting the parasite’s structure and metabolism. Pharmacological studies confirm that Albendazole acts as a potent inhibitor of tubulin polymerization within the parasite's cells. This targeted mechanism serves the fundamental goal of eliminating the organism, thereby interrupting the parasite's lifecycle and providing the necessary intervention for clearing intestinal parasite infections.

Regulatory References

  1. Albendazole MedlinePlus Drug Information

What side effects are possible with Albax?

Possible Side Effects and Safety Information

The possible side effects of Albax (Albendazole) are officially classified and documented by government regulatory bodies based on the affected organ system and frequency of occurrence. The safety profile identifies effects across several System-Organ Classes (SOCs), including the Nervous System, Hepatobiliary System, and Blood and Lymphatic System.

Adverse reactions are categorized by incidence. Common reactions (occurring in 1% to 10% of patients) typically include temporary increases in liver enzymes (transaminases), headache, reversible hair thinning (alopecia), and mild gastrointestinal symptoms such as abdominal pain or nausea/vomiting. Dizziness and fever are also commonly listed in official documents.

Regulatory documentation also highlights Serious Adverse Reactions, which are rare but clinically significant. These include bone marrow suppression (e.g., pancytopenia and agranulocytosis), severe hepatic abnormalities, and severe cutaneous reactions like Stevens-Johnson Syndrome. The risk of severe hematological and hepatic effects is primarily associated with prolonged, higher-dose systemic therapy.

Official safety notes define constraints for specific patient populations. Albax is contraindicated in pregnancy due to regulatory findings. Females of reproductive potential must follow specified contraception protocols during and immediately following treatment. Patients with pre-existing liver conditions are noted to be at an increased risk for adverse hepatic and hematological events, necessitating close monitoring of complete blood counts (CBCs) and liver function tests at the start of treatment and throughout therapy, as mandated by official labeling. Time-related safety patterns note that neurological effects (such as seizures) may occur early in the treatment of neurocysticercosis due to the inflammatory response following parasite death.

Overdose and Emergency Response

Overexposure to Albax (Albendazole) is documented in regulatory labeling focusing on specific manifestations and required emergency actions. Overdose may initially present with common systemic signs, including headache, nausea, vomiting, abdominal pain, and fever. However, more severe manifestations involve significant physiological changes, notably to the hematological system.

The official prescribing information documents the risk of bone marrow suppression, resulting in findings such as leukopenia, neutropenia, and severe pancytopenia. This hematological toxicity, along with the potential for elevated hepatic enzymes, defines the acute toxic risk profile of overexposure. Patients with pre-existing hepatic impairment are noted to be at an increased risk for the severity of these effects.

Regulatory guidance strictly outlines when urgent medical intervention is required. Immediate medical attention must be sought for any suspected overdose. Emergency Services (911) must be contacted if the exposed individual has collapsed, experiences a seizure, has trouble breathing, or cannot be awakened. Contacting a Poison Control Helpline is also a mandated step.

The official management protocol confirms that no specific antidote is known for Albendazole overdose. Consequently, the required treatment consists of symptomatic and supportive care, including continuous hospital monitoring of blood counts and liver enzymes to manage and track the resolution of the documented toxic effects.

Therapeutic Uses of Albax

What Albax Treats: Main Uses and Benefits

Albax (Albendazole) is an anthelmintic agent primarily used to help eliminate parasitic worm infections, addressing a wide spectrum of disease severity from common intestinal complaints to severe, life-threatening tissue invasion. It is applied in contexts marked by increased discomfort and physiological stress caused by helminths.

The medication is commonly used to help eliminate parasitic infections such as Neurocysticercosis, Cystic Hydatid Disease, and multiple intestinal helminths, including roundworms, hookworms, and pinworms. It is relevant for managing conditions that present with systemic or localized discomfort.

“Albax is relevant for managing conditions that present with systemic or localized discomfort and supports the patient during difficult episodes.”

Benefits in Symptom Management

This therapeutic domain is considered relevant for managing conditions where parasite larvae invade tissues, as well as clearing common gastrointestinal infections. The application provides support by helping to eliminate these invasive cysts, may assist with maintaining neurological functional stability and reducing the incidence of severe headaches. For intestinal infections, it supports patients by easing digestive distress and helps improve day-to-day comfort. Albax supports the patient during difficult episodes by addressing symptoms like unexplained weight loss and chronic debilitating fatigue that are linked to systemic imbalance.


Quick Fact: Relief for Abdominal Distress
Albax is commonly used to help eliminate the parasitic cause of chronic abdominal pain, diarrhea, and anal itching, providing supportive relief during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official regulatory documents define the eligible patient population for Alburex (Albumin [Human]) by stating absolute exclusions (contraindications) and populations that require conditional, highly restricted use.

Populations That Must Not Use Alburex (Contraindications)

Classification Restriction
Hypersensitivity Patients with a known allergy to human albumin or any excipients in the formulation are absolutely excluded.
Cardiovascular/Hematologic Use is prohibited in cases of severe anemia and cardiac failure (decompensated cardiac insufficiency) with normal or increased intravascular volume.

Populations Requiring Restricted or Conditional Use

Certain conditions mandate extreme caution and continuous monitoring due to the risk of hypervolemia (fluid overload) or hemodilution. The medicine must be used with caution in patients with hypertension, pulmonary edema, esophageal varices, hemorrhagic diathesis, and renal and post-renal anuria.

Age and Physiological Restrictions

  • Pediatric Use: Safety and effectiveness have not been established in formal clinical trials for children and adolescents, limiting routine use.
  • Pregnancy/Lactation: Alburex is generally used only if clearly needed during pregnancy, as it is not known if it can cause fetal harm or if it is excreted in breast milk.

What should I know about interactions with other medicines?

The official regulatory documents for Albax (Albendazole) define interaction patterns based on changes in the plasma concentration of its active metabolite, Albendazole sulfoxide, and the risk of additive toxicity.

Exposure-Modifying Interactions (Pharmacokinetic)

Co-administration of specific medicines significantly alters the exposure to the active metabolite. For instance, Praziquantel and Dexamethasone are documented to increase concentrations, with official data showing increases of approximately 50% and 56%, respectively. Cimetidine is also noted to increase concentrations, leading to a two-fold rise in bile and cystic fluid. Conversely, co-administration with CYP-inducing agents such as Phenytoin and Fosphenytoin decreases the plasma levels of the active metabolite by increasing its hepatic metabolism. Albendazole itself has been shown to induce Cytochrome P450 1A (CYP1A) in laboratory studies.

Interaction-Related Restrictions (Pharmacodynamic)

A critical restriction in the interaction profile involves pharmacodynamic toxicity. Combining Albax with other myelosuppressive agents, such as Ropeginterferon alfa 2b, carries the risk of additive myelosuppression, which is classified as a clinically significant interaction. This risk is noted to be heightened for specific patient populations, including those with liver disease or hepatic echinococcosis.

Dietary and Substance Constraints

The interaction profile also includes constraints related to ingestion. Taking the medicine with a fatty meal significantly increases its absorption and overall bioavailability. Additionally, consumption of Grapefruit juice may increase the effect of Albendazole by inhibiting the CYP3A4-mediated metabolism in the intestinal tract. No mandatory timing separation rules for co-administered drugs are explicitly stated in the official regulatory documentation.

Mechanism of Action

Albax is a competitive and reversible inhibitor targeting xanthine oxidoreductase (XOR), specifically both its oxidase and dehydrogenase forms. The primary location of this enzymatic action is the liver, where XOR is heavily expressed.

Molecule binding occurs at a site near the molybdenum-pterin active center of the XOR enzyme. This interaction structurally blocks the catalytic conversion of hypoxanthine to xanthine and the subsequent conversion of xanthine to uric acid, which are the terminal steps in the purine catabolic pathway.

This specific enzymatic blockade results in a downstream cascade characterized by a systemic decrease in the biosynthesis of uric acid. Consequently, the circulating and total body pool of uric acid undergoes concentration reduction. Furthermore, by inhibiting both forms of XOR, the formation of reactive oxygen species (ROS) that are catalyzed by the oxidase form is attenuated, leading to a modulation of cellular oxidative stress.

Dosage and Administration Information

Official Administration Guidelines for Albax

Albax, which contains Albendazole, is administered exclusively by the oral route using the tablet, chewable tablet, or oral suspension formulations. The drug's labeled instructions specify different administration patterns based on the infection being treated, distinguishing between systemic tissue disease and intestinal parasite clearance.


Administration Conditions and Dosing

All doses of Albax must be taken with meals. Taking the medicine alongside a fatty meal is a specific requirement, as it significantly enhances the amount of drug the body absorbs.

Indication Type Standard Adult Regimen Duration/Cycle Protocol
Systemic Infections (e.g., Hydatid Disease) 400 mg twice daily for patients 60 kg 28-day cycle, followed by a 14-day drug-free interval, for a total of 3 cycles.
Intestinal Helminths (e.g., Hookworm, Ascariasis) Typically a single dose of 400 mg Single dose or short courses (e.g., 1 to 3 days).

Population and Handling Rules

For patients weighing less than 60 kg with systemic infections, dosing is weight-based, calculated as 15 mg/kg/day divided into two daily doses, not to exceed 800 mg daily. Where swallowing is difficult, the tablets may be crushed or chewed and swallowed with water. If a dose is missed, standard protocols suggest taking it as soon as possible, but if it is near the time for the next scheduled dose, the missed dose should be skipped; doses should not be doubled.

Recent Clinical Evidence

Research evidence / Overview of studies for Albax

Evidence for Use in Tissue-Invasive Parasitic Cysts

The clinical evaluation of Albax in the context of infections where parasite larvae invade tissues is based on formal clinical trials and comprehensive reviews. The evidence base describing the use of medical treatment in this area is characterized by a large volume of data cited in regulatory reviews and clinical experience.

Cystic Hydatid Disease: Study Design and Outcomes

For Cystic Hydatid Disease, research has primarily focused on prospective clinical trials and systematic comparisons. Researchers monitored outcomes related to the cysts themselves, specifically measuring their resolution—whether they disappeared completely or reduced in size—using radiological scans. Researchers also monitored outcomes related to physical discomfort, such as changes in abdominal or chest discomfort.

Neurocysticercosis: Study Design and Outcomes

Research exploring the use of Albax for Neurocysticercosis in the brain includes formal Randomized Controlled Trials (RCTs). These studies were structured to compare patient outcomes when using Albax versus a placebo or another drug. Research monitored outcomes related to brain imaging, assessing changes in the appearance and number of lesions. Studies also monitored neurological functional stability, assessing how often participants experienced seizures or severe headaches, and follow-up on specific neurological outcomes, such as seizure frequency.

Evidence for Use in Common Intestinal Worm Infections

Albax was studied for common infections caused by intestinal parasites, including roundworm and hookworm, across numerous large-scale clinical trials and systematic reviews, often conducted in areas where these infections are common. Data show patterns related to frequently observed patterns in parasitological clearance markers for roundworm and hookworm, contributing significantly to the broader evidence landscape for these specific indications.

Long-Term Follow-up and Durability of Response

Studies for tissue-invasive cysts typically involve Medium to Long-term observation, monitoring patients for several months up to two years after the treatment course to assess the rate of parasitic recurrence. Conversely, evidence derived from field settings for common intestinal worm infections usually features Short-term follow-up, typically only a few weeks after treatment to confirm clearance. There is limited information for long-term outcomes regarding the prevention of re-infection in populations where re-exposure is common.

Key Studies & References

  1. Cysticidal drugs for neurocysticercosis: albendazole and praziquantel - NCBI
  2. Albendazole for the treatment of human echinococcosis: a review of comparative clinical trials
  3. Efficacy of Single-Dose Albendazole for the Treatment of Soil-Transmitted Helminthic Infections among School Children in Rwanda—A Prospective Cohort Study
  4. Albendazole - StatPearls - NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Albax (FAQ)

Q: Is Albax the same kind of medicine as [similar drug name]?

A: Albax contains the active ingredient Albendazole. Regulatory documents classify this substance as a benzimidazole carbamate compound, which means it belongs to a specific chemical family with anthelmintic (anti-worm) properties. This classification helps healthcare providers understand how the drug works compared to other medicines.

Q: Does Albax need to be taken at a specific time of day?

A: Official administration guidelines state that Albax is intended to be taken with meals, which helps the body absorb the medicine more effectively. However, the regulatory documents do not specify a mandatory time of day, such as morning or evening, for the medicine to be taken.

Q: Are there any common over-the-counter medicines that are known to interact with Albax?

A: The official product information lists specific prescription medicines, such as Cimetidine and Phenytoin, that can interact with Albax by changing its concentration in the body. While a specific list of common over-the-counter (OTC) medicines is not provided, official guidance emphasizes the importance of informing a healthcare provider about all medicines and supplements being used.

Q: Can people with a known history of [minor chronic condition] use Albax?

A: Official documents highlight that patients with pre-existing conditions, particularly those involving liver dysfunction, may be at an increased risk for side effects and require close monitoring. Use in the presence of any chronic condition requires careful consideration of the potential benefits and known risks, as described in regulatory documents.

Q: Is it normal to feel [mild, common side effect] when first starting Albax?

A: Common side effects, which occur in 1% to 10% of patients, include headache, abdominal pain, and nausea. Regulatory safety notes also indicate that neurological symptoms like seizures can sometimes occur early when treating neurocysticercosis, which is related to the inflammation caused by the dying parasites.

Q: Why does the official document mention a specific age limit for using Albax?

A: Regulatory bodies note that there is limited clinical experience with Albendazole in children under 2 years of age. Due to this, regulatory guidance generally indicates that the medicine is not recommended for use in this very young age group.

Q: Can Albax affect the results of certain medical tests?

A: The official label mandates the close monitoring of Complete Blood Counts (CBCs) and Liver Function Tests during treatment. This monitoring is required because Albax can cause changes in the liver and blood systems, which are reflected in the results of these medical tests.

Q: Does Albax have a sedative effect?

A: Official labeling lists dizziness as a common side effect and notes that somnolence (sleepiness) has been reported in rare cases. Because of these potential effects, official documentation indicates that patients should be aware that the ability to drive or operate machinery may be impaired due to these effects.

Q: What are the official restrictions on using Albax during pregnancy or breastfeeding?

A: Albax is officially contraindicated in pregnancy. Official guidelines specify that females who can become pregnant are required to use effective contraception during and immediately following the treatment period. It is also generally advised to avoid breastfeeding because it is unknown if the medicine can pass into breast milk.

Q: Is it possible to take Albax if you have kidney or liver issues?

A: The official product information states that patients with pre-existing liver disease are at an increased risk of side effects and require careful monitoring. Some regulatory texts also mention that the drug should be used with caution in patients with renal impairment (kidney issues).

Q: Why do people sometimes need to adjust their dose of Albax?

A: Dose requirements can vary based on a patient’s body weight for certain types of systemic infections. Additionally, if monitoring tests show significant increases in liver enzymes or decreases in blood cell counts, the dose or treatment course may be modified based on changes in blood tests, as noted in the official safety guidance.

Q: Is there a difference in how Albax works in children versus adults?

A: While the regulatory documents note different dosing requirements for children, primarily based on weight, the fundamental mechanism of action—how the medicine targets parasites in the body—is generally considered the same for both adult and pediatric patients.

Q: Is the onset of action different depending on the formulation (e.g., tablet vs capsule)?

A: Official guidance emphasizes that taking the medicine with a fatty meal greatly enhances its absorption regardless of the form used (tablet or suspension). Regulatory documents do not specifically state a difference in the speed of the effect (onset of action) between the various formulations.

Q: Can Albax be taken while operating heavy machinery?

A: Due to common side effects like dizziness and headache, regulatory documents advise that patients should be aware that their ability to safely drive or operate heavy machinery may be impaired while taking Albax.

Q: What is the evidence regarding Albax and quality of life measures?

A: Clinical studies reviewed by regulatory bodies monitored patient outcomes related to symptoms that directly impact daily life, such as changes in abdominal discomfort and the frequency of seizures for specific conditions. These results contribute to the overall evidence base on how the drug affects patient well-being.

Q: How long does the effect of Albax last?

A: Regulatory documents describe the period required for monitoring parasite recurrence, which can range from short-term to several years for some infections. The half-life of the active component in the blood is typically reported to be around 8 to 12 hours in pharmacokinetics data.

Q: Does Albax contain [common allergen, e.g., gluten or lactose]?

A: The official product information lists all the inactive ingredients (excipients) used in the medicine. Patients with concerns about specific allergens like lactose, sucrose, or gluten should consult this section of the label or consult the full product information.

Q: Are there any common beverages, like coffee or tea, that are described as interacting with Albax?

A: The official interaction profile specifically notes that Grapefruit juice can increase the concentration of Albax in the body. No explicit interaction is noted in regulatory documents for common beverages such as coffee or standard tea.

Q: What is the general safety classification of Albax according to government bodies?

A: Albax is formally classified by regulatory bodies as a Prescription Only Medicine (POM). It is also designated with a strong warning, such as a Pregnancy Contraindication, due to the potential risks shown in regulatory findings.

Q: Do studies suggest Albax is appropriate for older adults?

A: Regulatory documents indicate that while there may be limited clinical experience in patients aged 65 and older, generally no dosage adjustment is required based on age alone. Caution is advised for elderly patients who also show signs of liver dysfunction.

Q: Is it necessary to avoid sunlight while taking Albax?

A: The official lists of common and serious adverse reactions do not typically include photosensitivity or warnings that patients must avoid sun exposure while taking Albax.

Q: Is Albax available as a generic medicine?

A: Yes, regulatory records confirm that the active ingredient, Albendazole, is widely available in generic versions, which are produced by different manufacturers in addition to the original branded formulations.

Q: Are there any natural supplements described as interacting negatively with Albax?

A: The official interaction profile lists specific drug interactions and notes that Grapefruit juice may increase drug levels. It is important that a healthcare provider is made aware of all supplements, herbal products, and vitamins being taken for a complete review.

Q: How long does Albax stay in your system after the last dose?

A: The half-life of the active component, Albendazole sulfoxide, which is the time it takes for half the drug to be eliminated, is generally reported in regulatory documents to be around 8 to 12 hours.

Q: Does Albax cause weight changes?

A: Weight changes, including both gain and loss, are not listed among the common or serious adverse reactions that are documented in the official regulatory documentation.

Q: What does the term 'drug interaction' mean in the context of taking Albax?

A: A drug interaction means that a co-administered substance can change how Albax works in the body. This can happen by changing the amount of Albax present (like how Phenytoin decreases its levels) or by increasing the risk of additive side effects (like the risk of low blood cell counts with myelosuppressive agents).

Q: Does Albax interact with alcohol?

A: Official safety sources do not provide a clear answer on whether drinking alcohol specifically interacts with Albendazole. Regulatory documents note that the impact of alcohol consumption on Albendazole is not clearly defined.

Q: Where can I find the official regulatory document (like the FDA label or EMA SmPC) for Albax?

A: The full official document, such as the FDA Prescribing Information or the EMA Summary of Product Characteristics (SmPC), is publicly available directly on the websites of the relevant government regulatory bodies, including the FDA, EMA, and MHRA.

Q: Is Albax habit-forming?

A: Albax is not classified as a controlled substance by regulatory agencies and is not considered habit-forming based on official drug classifications.

Q: Does Albax affect blood pressure?

A: Blood pressure changes, specifically high blood pressure (hypertension) or low blood pressure (hypotension), are not listed among the common or serious side effects in the official regulatory documentation.

Q: Is a prescription required to obtain Albax?

A: Yes, Albax is formally classified by regulatory bodies as a Prescription Only Medicine (POM). It can only be obtained with a valid prescription from a licensed healthcare provider.

How should Albax be stored and disposed of?

How to Store and Dispose of Albax?

The official storage and disposal guidelines for Albax (Albendazole) are set by regulatory authorities to ensure product stability and public safety.

Storage and Handling Requirements

Condition Rule
Temperature Store at room temperature (not exceeding 30 C).
Protection Keep the medicine protected from light and away from excess heat and moisture.
Container Store in the original container and keep it tightly closed.
Stability Do not use Albax after the expiry date printed on the packaging.

Child Safety and Disposal

  • Child Protection: It is mandatory to keep this medicine out of the sight and reach of children and store it locked up.
  • Disposal: Do not throw away Albax via wastewater or household waste. Consult a pharmacist or follow local regulatory requirements to dispose of unused or expired medicine safely.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Albax found in:

A-Z Index: